Professor of Bioinformatics, Institute of Molecular Life Sciences (IMLS) and Swiss Institute of Bioinformatics (SIB), University of Zurich
Member of Global Alliance for Genomics and Health (GA4GH)
Professor Marvin Caruthers has been active in biotechnology since 1980 when he, along with several other scientists and venture capitalists, was a co-founder of Amgen and Applied Biosystems. The chemical methodologies he developed for synthesizing DNA and RNA represent one of the cornerstone technologies leading to the success of these two companies and generally the revolution in biotechnology. Since then he has been a co-founder of several additional biotechnology companies with miRagen Therapeutics being the most recent. Through the early history of these companies, he will outline the challenges and rewards of starting new biotechnology companies.
Blockchain is the one of the most talked about technologies .With the potential exceeding any other to revolutionize the healthcare industry, it is crucial to first understand the nature of blockchain technology, to distinguish the hype from the reality and then to see real-world case studies of how blockchain, combined with other technology such as AI, will be applied to healthcare systems.
This speech will talk about the hope, the disillusion and the reality check of Artificial Intelligence as a tool utilized in modern medicine. The focus will be on real examples as well as promising developments. Additionally, the scope will touch a variety of different specialties in health care, and won’t stop at imaging processing only, as in many current discussions.
Last but not least, the discussion will provide a business view for both, vedors and healthcare organizations alike.
Medicine is reaching a turning point: Experts believe that in just a few years, artificial intelligence will greatly help doctors make diagnostic decisions and plan treatments. In addition, patients are expected to benefit from increasingly personalized approaches and better care. This talk will present a number of examples that show how AI can make an impact at different levels along the healthcare workflow and can pave the way for precision medicine and advanced decision support.
Dr Helen Rostill, Director of Innovation and Development at Surrey and Borders Partnership NHS Foundation Trust and Payam Barnaghi, Professor of Machine Intelligence at the University of Surrey will discuss the importance of cross collaboration between the NHS, industry and academia as health providers struggle to meet the needs of ageing populations. They will cover the innovative TIHM (Technology Integrated Health Management) for dementia project that is using artificial intelligence to enable clinicians to identify and predict ill health in people with dementia living at home as well as other innovative studies that they are involved in. They will also discuss the operational, financial, technological and regulatory challenges of cross-collaborations in health.
The presentation is based on my journey as a heart patient and athlete. How using data from my implanted device, wearable devices and performance signals allowed me to get my life back. Next how do we scale my success to others and have a positive impact on the patient experience. How cloud computing enables these solutions.
The biopharma industry continues to face challenges this year, with projected returns on investment in R&D at the lowest levels since our analysis began in 2010. However, there are opportunities to reverse this trend, which will require new ways of working and a complete digital transformation to unlock R&D productivity and deliver the next generation of scientific breakthroughs.
Networking Dinner - Sponsored by:
Multi-layer omics (genomics, transcriptomics, proteomics and metabolomics) data stores, intuitive user interfaces and automated bioinformatics processing pipelines build the bases for integrating heterogeneous data for cancer care and research. Our data-driven process has been instrumental in a multitude of clinical oncology studies and builds the basis for Tübingen’s approach to individualizing cancer therapy via epitope-based vaccines. Through the implemented process for data and project management we were able to reach a high degree of automation on the way from tumor tissue to the presentation in the molecular tumor board.
The optimisation trajectory of hit to lead to candidate is the most expensive part of drug discovery. Exscientia’s Centaur drug discovery platform brings that cost down significantly by combining the strengths of AI compound design and human strategic thinking. A high level overview of the technology is presented and results are shown from a successful collaboration that resulted in the delivery of a clinical candidate in less than a year.
Developing a novel, highly disruptive approach to gene synthesis, the technology which underpins the rapidly growing field of synthetic biology. There are two key components of this approach:
The selective and controlled annealing of oligonucleotides in a building process aimed at assembling DNA with very low error rates. The advantages of our technology are therefore massive parallelism and the ability to synthesize DNA at scale and with improved fidelity.
Processing, understanding, and reasoning on massive, high-clinical, dimensional data towards predicting clinical outcomes
During this presentation I will discuss the changing world of radiology and how AI based solutions and quantification are disrupting this field. This will not only impact the way medical images are interpreted and used in clinical decision making, but will also broaden the possibilities of imaging for real world and big data studies.
docdok.health is a Swiss Digital Health StartUp that has developed the innovative physician-patient communication platform docdok. docdok offers a solution to key pain points at the physician-patient interface. Physicians access a single digital platform for integrated secure patient communication. docdok integrates directly with the EMR and also connects to multiple patient healthcare devices. For the physician, this allows seamless streamlining of all incoming communication and data through a single channel. Every interaction is logged for liability protection and billing purposes. docdok also enables automated dissemination of appointment reminders, patient surveys and personalized content, including tailored disease management solutions. For the patient, it means easy access to the physician and personal health information through an app as well as improved care in between visits. Using the same front-end, docdok enables research organizations (e.g. university hospitals), pharmaceutical and medtech companies to conduct studies involving patient-reported outcomes and real world data capturing.
mRNA therapeutics are more in the spotlight today than ever before. Up to 20 clinical trials in various indications are ongoing by various companies in the fields of vaccines, enzyme replacement therapies, and oncology. mRNAs can be applied in vivo, comprising several different proteins as cocktails, all expressed in the same tissue. Currently undruggable targets, such as membrane receptors and intracellular proteins, can be expressed, offering a whole new horizon for treatment options. Furthermore, each patient can be analyzed and treated individually by an mRNA vaccine or therapeutic just printed at the doctor’s office. A vision or near-term reality?
Professor of Bioinformatics, Institute of Molecular Life Sciences (IMLS) and Swiss Institute of Bioinformatics (SIB), University of Zurich
Member of Global Alliance for Genomics and Health (GA4GH)
Presentation on the feasibility and benefits of creating a vendor/pharma independent, open source, Blockchain network to keep the real identity of the patients protected while allowing the possibility to:
Do patients really care about their healthcare data?
Some great patients initiatives in France:
- Renaloo "Moi patient" platform initiative
- Seintinelles: patients sharing data for research on cancer
Conclusions: difficulties for patients to access data ; patient's new generations
Dr Helen Rostill, Director of Innovation and Development and Payam Barnaghi Professor of Machine Intelligence at University of Surrey, will discuss the TIHM (Technology Integrated Health Management) for dementia study, the first programme of work – in the UK or internationally – that has developed and installed an Internet of Things based intervention to support management of dementia in the community. They will cover the pioneering work in developing machine learning algorithms to support early intervention and reduce people’s need for hospital admission. One of the algorithms designed can detect the symptoms of a urinary tract infection, a top five cause of unplanned hospital admission among older people in the UK.
Senior R&D executives: Scientific Officers, Chief Information Officers, Chief Technology Officers, Knowledge & Data Management (Discovery, Clinical & Real-World Data), R&D Analytics, Informatics, R&D Innovation, External Alliances & Innovation, R&D Strategy.
Drug Discovery: Drug Discovery, R&D, Lead Identification & Target Validation, Screening, Translational R&D, Genomics & Proteomics, Biomarker R&D, Senior Scientist, Biostatistics, Biometric, Precision Medicine, Personalised Medicine, Computational Biology.
R&D and IT Infrastructure: Information Technology & Services, R&D IT, IT Hardware & Infrastructure, Software, Database Management, Vendor management
Data Management: Clinical Development, Clinical Data Management, e-Clinical, Electronic Data Management, Health Economics & Outcomes Research, Real-World Evidence Generation, Late-Phase Research, Epidemiology, Drug safety & Pharmacovigilance, Medical Information.
Digital & Connected Health: eHealth, mHealth, Connected Health, Digital Health Solutions, Strategic Medical Innovation, Business Development, Strategic Collaborations, Alliances, External Innovation, Patient Engagement
Global Head Technology, Architecture, Digital Drug Development
Senior Technologist and Enterprise Digital Architect, Pascal has more than 20 years of experience leading global IT organizations, building high performing teams, managing Enterprise Architecture teams, leading digital innovation and delivering complex large scale, global programs. He joined Novartis and the Pharma industry in 2013 and is in charge of the technology evolution of the Drug Development Information System. Passionate by the new technology and by the transformation of the healthcare industry, excited to deploy a mix of Digital, IT technology, semiconductor and pharmaceutical knowledge to drive the acceleration in eHealth and digital medicine, Pascal advocates for a Blockchain consortium to accelerate the adoption of this technology in the healthcare in the industry
Senior Vice President and Head Global Clinical Development, Chief Medical Officer
Merck Sharp and Dohme, USA
Roy Baynes is Senior Vice President and Head, Global Clinical Development and Chief Medical Officer at Merck Sharp & Dohme (MSD). He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.
Co-founder and Chairman of the Supervisory Board
CEO and co-founder of the biopharmaceutical company CureVac AG, incorporated in 2000, is Dr. Ingmar Hoerr. His entrepreneurship was motivated by a surprising discovery during his doctoral research at the University of Tuebingen. Experiments conducted for his research showed that the mRNA molecule class can be injected into tissue directly and is capable of expressing genes into proteins effectively as well as generating a strong specific immune response, contrary to what had previously been believed. From this key discovery, the founders built up a company that was the first ever to treat a human subject with an mRNA drug and that is now a leading German “unicorn” in the research and development of mRNA-based drugs.
Ingmar Hoerr received his PhD from the University of Tübingen and his MBA from Danube University, Krems, Austria. He currently advises the European Commission as member of the High Level Group of Innovators in developing a European Innovation Council and is juror of the founder prize Weconomy.
Associate Director, Information Systems
Andrea Splendiani (M), PhD is Associate Director in NIBR Informatics. He has more than 15 years of experience in data integration, ontologies, and semantic web technologies. A computer scientist by background, he has been working in a variety of roles and life sciences environments, including functional genomics, systems biology and knowledge engineering. His professional activities and research focus on the interface between knowledge organization and its downstream exploitation. Since 2014 he is in Novartis, where he is responsible for the development of advanced data curation approaches
Principal Scientist, Scientific Information Management
Roche Innovation Center Basel, Switzerland
Martin is a Data and Information Architect in Technical Solution Delivery and Architecture in Pharma Research and Early Development Informatics at F. Hoffmann-LaRoche. His main areas of activities are terminology management, semantic engineering, scientific data curation, text mining and semantic search. Martin has been active in the development and deployment of Data Standards within the organization but also teaming up with external partners. During his work Martin puts a particular emphasis on cross-functional data organization and the definition for Data Quality KPIs. As a part of pREDi's precompetitive engagements Martin has been contributing to projects of the Pistoia Alliance and the Innovative Medicine Initiative.
Before joining Roche Martin worked at the Novartis Institutes of Biomedical Research as a Senior Knowledge Engineering Consultant leading various ontology development and text mining projects such as the implementation of a set of BioAssay Ontologies. Martin was also the Managing Director of a Start-Up company in Freiburg (Germany) where he focused on R&D activities for NLP. He holds a PhD in Computation Linguistics from the University of Freiburg on Semantic Interpretation of technical and medical texts.
In the past 20 years Istvan J Enyedy has been involved in new target
evaluation, hit finding, and hit-to-lead optimization projects for several types of target classes using both ligand and structure-based methods. He is coauthor on more than 40 publications and 12 patents/applications. He received his PhD in 1998 at Catholic University of America, Washington DC, and did postdoctoral training in Dr. Shaomeng Wang’s group at Georgetown University Medical Center, Washington DC. Between 2001 and 2008 he worked at Bayer Pharmaceuticals, West Haven CT and Novartis Institutes for Biomedical Research in Cambridge MA. Since August 2008 he has been working at Biogen Idec, in Cambridge MA.
Principal Scientist, Toxicology Project Leader
Alessandro Brigo is a Principal Scientist and Toxicology Project Leader in the Pharmaceutical Sciences organization at the Roche Innovation Center Basel, Switzerland. In this role Alessandro leads drug discovery and development programs from a toxicology perspective to provide expert support through all development phases and for marketed products.
In addition, Alessandro has been working in the field of Computational Toxicology since 2006, with great emphasis on the assessment of potential genotoxic impurities in active pharmaceutical ingredients at development and marketing stages. On the topic, Alessandro authored and co-authored 6 peer-reviewed articles and 3 book chapters.
Being highly interested in storage, accessibility and interpretation of large and complex datasets, between 2010 and 2016, Alessandro has been serving as global business lead of the Roche Safety Data Integration (SDI) initiative and the SEND-readiness program, both of which aim at delivering Standards for Integration and Exchange of Nonclinical Data.
Alessandro is a pharmacist by training with a PhD in Pharmaceutical Sciences obtained at the University of Padua, Italy, and a board-certified toxicologist (DABT).
Global Head of Portfolio Management, Medical, Digital and RWE Solutions,
Peter Speyer is Global Head of Real World Evidence Solutions at Novartis, responsible for managing and expanding Novartis’ Real World Evidence data and technology infrastructure, as well as creating visualizations and apps to make the data useful across the organization. Prior to his role at Novartis, Peter was Chief Data & Technology Officer at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington in Seattle. In that role, he was responsible for obtaining and managing the data that fuel IHME’s research in global and public health, and for providing powerful computational infrastructure that enables cutting edge analytics. To make IHME’s data and research results useful for others, he directed the development of the Global Health Data Exchange (GHDx) and IHME’s innovative interactive data visualizations.
Prior to joining IHME, Peter spent most of his career in strategy and product management positions in the media industry. He worked most recently in a number of leadership positions at image licensing company Corbis, including Director of Market Strategy and Director of Product Management. Before Corbis, Peter held positions in Corporate Strategy and the TV subsidiary RTL Television at German media giant Bertelsmann.
Peter holds an MBA from Temple University in Philadelphia, USA, and a Master in Business and Engineering from the Karlsruhe Institute of Technology, Germany.
Senior IT Project Manager Specialized in Health IT
Benoît has an IT Master Degree from the University of Technology of Compiegne (France) and has more than 25 years’ experience leading various digitalization projects to improve and streamline the clinical research process. Before joining Roche, Benoît created and managed the startup NovaXon that provided solutions to pharmaceutical companies and hospitals to collect clinical data. Previously he worked for Medtronic in a special innovation department to explore new therapies with active medical devices. Most recently, he took the position of Roche representative in the industry collaboration EHR4CR and became a strong advocate both internally and externally of the potential of hospital real world data to support medical research. In parallel Benoît, is leading several innovation proposals to address some of the common challenges observed in precision medicine.
Head of Discovery Informatics
Jonny Wray is a computational biologist with a unique background in complex systems analysis, computational biology, drug discovery informatics, and software engineering. Jonny was a Fellow in Theoretical Neuroscience at The Neurosciences Institute (New York and San Diego) where his research was aimed at understanding how brain function arises from network structure. More recently, Jonny was Director of Bioinformatics at Five Prime Therapeutics (San Francisco) where he was responsible for the informatics portion of Five Prime’s discovery platform. Jonny is currently the Head of Discovery Informatics at e-Therapeutics plc where he has been responsible for the conceptual development of their network driven discovery approach, and the design of the software platform embodying that approach.
Head Computational Biology and Stats, Target Sciences
GSK R&D, UK
Philippe is currently the Head of the Computational Biology and Stats Department at GSK (GlaxoSmithKline) and a GSK Senior Fellow. He is also the GSK lead for Open Targets an innovative pre-competitive collaboration located on the Genome Campus in Hinxton (UK) between the WTSI (Wellcome Trust Sanger Institute), the EBI (European Bioinformatics Institute), Biogen, Takeda, Celgene and GSK. He is also a member of the Scientific Advisory Board for the GSK and EMBL-Heidelberg strategic partnership. He serves on several academic advisory boards and funding panels in the UK and Europe. He has published more than 50 peer-reviewed papers in bioinformatics, genomics and genetics. Philippe has a PhD from the University of Rennes in France. His post-doctoral training was at the Imperial Cancer Research Fund in London (now Cancer Research UK) with a focus on Immunogenetics before joining GSK.
John Griffin is Chief Scientific Officer at Numerate, which has developed and applies an AI-driven approach to small molecule drug design. He was formerly Co-Founder and Chief Scientific Officer of Theravance and Assistant Professor of Chemistry at Stanford. John is the author of 39 publications, an inventor of 27 issued patents, and the recipient of awards including a Cope Scholar Award from the ACS and a Dean's Award for Teaching from Stanford University. John received a B.S. in Chemistry from Hope College, a Ph.D. in Chemistry from Caltech and was a Postdoctoral Fellow at Harvard Medical School.
Background in mathematics and computer science with extensive experience implementing highly scalable infrastructure and system architecture for web-based projects. Currently, he is leading R&D team of Insilico Medicine applying deep learning techniques to drug discovery, biomarker development and aging research with interdisciplinary applications of blockchain solutions to healthcare. Co-authored several educational projects in academia and MOOCs.
Image Analysis Group, UK
Mathematician with expertise in actively managing innovation in life science companies, asset positioning, strategy, and bio-pharma investment. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health. Olga is an active researcher, co-author of 60+ publications, books, and book chapters. She is a scientific adviser to the UK government and EU funding bodies. She is a founding member of 'The 2% club' to support women in leadership positions, fellow of the Royal Society of Medicine, Royal Society of Engineering, alumni of several business leadership programs by Goldman Sachs, Oxford Said Business School, Business School of University of Leeds, alumni of Business Programme by the New York Economic Development (New York Venture Fellows), 4-time winner of the national and international 'Entrepreneur of the Year' award.
Founder and CEO
Yann is a seasoned Pharma R&D professional, strategy consultant and biotech entrepreneur with 20+ years of experience in pharma (Servier, Ipsen), molecular diagnostics (IntegraGen) and strategy consulting (Capgemini Consulting, BearingPoint, Cepton). Yann is also a skilled data scientist with several patents and publications in the field of biostatistics and biomarkers discovery and validation.
Since 2016, Yann is the co-founder and CEO of of Iktos, a Paris based start-up company and one of the leading players in the emerging field of AI for chemical research. Iktos is focused on the development of innovative IA solutions (services and software) for de novo drug design (both ligand-based and structure-based), leveraging the recent developments of deep learning technology and more specifically DL generative models.
Yann holds a MS Degree from Ecole Polytechnique Paris and a MS Degree in genetics from AgroParisTech.
Nebula Genomics, USA
Dennis is the Co-founder of Nebula Genomics. He holds the Boehringer Ingelheim PhD Fellow in Genetics and Genomics at Harvard University. He is also a member of German National Academic Foundation Fellowship and holds Master's in Computer Science from Harvard University.
Co-Founder & CSO
Axel has over 20 years of R&D leadership experience in genomics, epigenetics, biomarker discovery, Bio-IT, and aging & longevity. He is the Author of the ‘Blockchain & Healthcare Strategy Guide’, the standard compendium for the healthcare industry. Axel translates scientific discoveries into practical applications to help understand, diagnose, and treat complex disorders, but also to promote cutting-edge technologies that could transform precision medicine and the way we age. Axel is a Faculty-Member of the Blockchain Research Institute in Toronto and holds a PhD in Human Genetics from the University of Cologne.
CEO, Evonetix, UK
Tim Brears was appointed Chief Executive Officer of Evonetix in May 2017. He previously served as Chief Executive of a number of bioscience companies, including Xention, a biopharmaceutical company specialising in the discovery and development of ion-channel-modulating drugs for the control of atrial fibrillation, and Gendaq, a company focused on the development of zinc finger proteins for gene regulation.
Prior to that, he spent ten years in the US, initially as a long-term fellow of the European Molecular Biology Organisation at Rockefeller University, New York, and subsequently as Director of Licensing at Ciba-Geigy (later Novartis) Agribusiness in Research Triangle Park, North Carolina.
Tim holds a PhD in molecular biology from Cambridge University and an MBA from Duke University’s Fuqua School of Business and is a Registered US Patent Agent.
Gareth Conduit has a track record of applying artificial intelligence to solve real-world problems. The approach, originally developed for materials design, is now being applied to design of small molecule pharmaceuticals. The method is being commercialized by startup Intellegens in collaboration with Optibrium. Gareth also maintains an academic position at the University of Cambridge.
Co-Founder & CEO
Ulrich Muehlner is a senior healthcare executive with 18 years of industry experience. In 2016, he started GrowthCube Partners and became an active startup investor and entrepreneur to enable life-changing healthcare innovations by joining forces with scientists, innovators, and entrepreneurs, and - together - translating groundbreaking ideas, discoveries, and inventions into services and products that make a real difference to people’s lives. Dr Muehlner is particularly passionate about transforming the pharma & medtech industry and providers towards value-based healthcare through Real World Evidence, Artificial Intelligence, and Deep Learning. To fulfill this mission, Ulrich Muehlner co-founded docdok.health and developed docdok, a GDPR and HIPAA compliant cloud based solution connecting healthcare providers with their patients in the clinical and study ecosystems, 24/7, on all devices enabling to capture objective real world data (RWD) in addition to subjective patient reported outcomes (PROs) while significantly benefiting both patients and doctors. He also serves globally as board member and advisor to biopharma and digital health/health tech companies (e.g., E-Medicus, Insilico Medicine, Medicinisto), as well as international organizations and leading academic institutions. Previously, Dr Muehlner worked at Novartis and Boston Consulting Group (BCG). At Novartis he served as Director and Head Global Corporate Strategy, Global Head Outcomes Technologies Incubator. In these roles, he was responsible for the multi-billion dollar portfolio transformation strategy and spearheaded globally the digital health activities across Novartis leading to major digital health partnerships (Google/Verily, IBM, Proteus) with the aim to increase the value of the Novartis portfolio through ‘beyond-the-drug’ real-world outcomes solutions. In total, Dr Muehlner successfully executed deals with a volume of $350mn. Ulrich Muehlner studied Biochemistry in Hannover and Munich, and earned a PhD degree in Biochemistry and Molecular Biology based on his research on molecular mechanisms of cancer development at the Research Institute of Molecular Pathology (I.M.P.) in Vienna.
VP Pharma (EMEA)
Aji is a biochemical engineer and health economist who has spent the past 16 years in various healthcare focused roles. From studying the development of gene therapies to global market access and now at the cutting edge of healthcare technology.
As the business development director at HealthUnlocked he works with academic and industry partners around the world in the design, deployment and measurement of digital health interventions.
Co-Founder and CTO
Zebra Medical Vision, Israel
Eyal Toledano is co-founder and CTO of Zebra Medical Vision; Eyal focuses on innovation in medical imaging machine vision. Graduated with Master of Science from the MIT Media Lab. Eyal served for more than 8 years as the CTO and Advanced Technology GM for Samsung Israel R&D (STRI/Yakum). Eyal was responsible to envision, establish and manage new technological domains such as computer vision, augmented reality, and the Medical Imaging lab in Samsung Israel R&D. Before co-founding the Israeli R&D of Samsung Eyal was leading the development of challenging projects at Sun Microsystems. Eyal Toledano completed 7 years of military service in the IDF Elite Intelligence Technologies unit as officer and team leader. Eyal still hacks code every day, father to 5-year-old Yuval enjoys scuba diving, tennis and jazz.
Wim Van Hecke, PhD, is the founder CEO of icometrix. icometrix the world leader in software solutions to obtain clinically meaningful data from brain imaging scans. The fully automated icobrain software is FDA approved and has market approval in Europe, Canada, South America and Australia. The icobrain software is used in 100+ hospitals and icometrix works with the largest pharmaceutical and health tech companies for real-world and big data studies.
Wim is an academic engineer by training with two Masters degrees in applied biomedical engineering and neuroimaging, and a PhD in diffusion MRI analysis. He is author or co-author of over 150 scientific publications, has won numerous scientific awards and is frequently invited to present his work at courses, conferences and hospitals around the world.
Head of Chemoinformatics
Willem van Hoorn gained a PhD in computational chemistry in the group of David Reinhoudt at the University of Twente, the Netherlands followed by a postdoc at Yale with Bill Jorgensen. He subsequently spent a decade at Pfizer Sandwich focusing on computational techniques for HTS triage and combinatorial library design. This was followed by a position as IT consultant at Accelrys (now Biovia) assisting a range of clients from small biotech to big pharma. Since 2013 he is pursuing his long term interest of applying computer algorithms to drug discovery at Exscientia.
Founder & CEO
Elin Haf initially qualified as a Children’s nurse at Great Ormond St Children’s Hospital (GOSH), going on to gain a BSc (Neuroscience) and MSc (Research Methods). After years of recruiting children to clinical trials Elin embarked on a PhD at the Institute of Child Health (UCL) to develop a clinical outcome measure and biomarker of ataxia in children with neuro-metabolic disease.
Elin Haf was part of the paediatric team at the European Medicine Agency from 2007-2013, responsible for implementing the Paediatric Regulation in Europe. She has a personal interest in empowering children to become involved in the health / research agenda.
In January 2015 Elin Haf launched her own company, Aparito. Using wearable technology and mobile phone apps to monitor disease progression and patient well-being in real-time. The company now has studies running in the UK, India, America, South Africa, with offices in London, Berlin and Wrexham.
When not working Elin is an adventure-addict! She played rugby for Wales A for seven years before embarking on a completely new challenge - spending 77 days rowing across the Atlantic Ocean with fellow GOSH nurse and raising £190,000 for metabolic research. In 2009 she was part of the first ever-female crew to row across the Indian Ocean, a 3,600m trip that took 78 days. Elin Haf completed a hat-trick of oceans by sailing 6,000 miles across the north Pacific. Her adventures over the years have raised £300,000 for charities close to her heart. Her book, On Tempestuous Seas holds the record for the most number of books sold in one night at the National Geographic Store in London.
Elin was appointed Team Wales Ambassador for the 2018 Commonwealth Games in Australia
More details at www.elinhafdavies.co.uk or @elinhafdavies
And www.aparito.com and @aparitohealth
Co-founder and CEO,
Following his studies at Ecole Polytechnique, Alexis Mathieu started FeetMe facing strong unmet clinical needs within rehabilitation. Starting form sensors design up to market access, Alexis has lead the different stages of the company within strong regulatory constraints.
Alexis has built a team of 15 engineers, with broad expertise, ranging from physics to signal processing and biomechanics. He has set up a strong tech culture, including a focus on testing. For example, team members get to “dog food” the product they are building and jog around wearing the insoles, which is a testimony of their dedication! In addition, the team works day to day with physicians and key opinion leaders.
In a matter of months, Alexis has learned to speak a clinician’s language and has built the solid relationships that are crucial to successful medtech innovation.
Chief Executive Officer, Chief Scientist, TheraPanacea, France
Nikos Paragios (45), CEO and CSO of TheraPanacea, is also a distinguished professor of Mathematics and computer science, former director of the Center for Visual Computing at CentraleSupelec (Université Paris Saclay) and the Galen research team at Inria. Nikos has held numerous academic and industrial appointments in USA (visiting professor for Yale and Rutgers University and as an R&D manager for Siemens USA), received many prestigious international prizes for his work on the application of Imaging technology and AI to medical sciences (including the very selective MIT Under 35 global awards (2007) and the ERC grant from Europe (2011), granted to less than 1% of European researchers.
Founder and Managing Partner
Pool Global Partners, USA
Sally Daub is a technology entrepreneur, investor and CEO. An experienced executive, Sally’s industry-wide expertise includes semiconductors, consumer electronics, AI applications in healthcare, quantum computing and blockchain, making her an in-demand advisor and board member to both private and public companies in Silicon Valley and Toronto.
As Founder and Managing Partner of Pool Global Partners, Sally is investing in the next generation deep technology innovation. Pool Global Partners combines Sally’s extensive experience in founding, funding and scaling technology companies with a global network of partners and operators. With an emphasis on operational expertise and concept-to-commercialization strategy, Sally has guided numerous technology companies through successful investor exits and IPOs.
A frequent lecturer and guest speaker at universities and events around the world, Sally is also a Fellow at Creative Destruction Lab, a leading deep technology innovation pipeline and accelerator program, where she provides mentorship to promising entrepreneurs.
Sally has been recognized with numerous awards, including Women’s Executive Network’s Top 100 Most Powerful Women (2010, 2011, 2012, 2013) and inducted into WXN’s Hall of Fame (2014).
Principal Scientist - Medical Biomarker Research Oncology
Ralf Hoffmann is a Principal at Philips Research in Eindhoven, The Netherlands. He holds a PhD in Protein Biochemistry and Molecular Biology and an MSc in Biology from the University of Constance, Germany. After his time as a Postdoc at the University of Constance and at the University Hospital in Ulm, Germany, he moved to Sandoz Pharma, Basel, Switzerland to analyse the function and regulation of phosphodiesterases in inflammatory processes associated with asthma. After the merger between Sandoz Pharma and Ciba Geigy, he was working on target discovery for therapeutic applications in the field of Neuroscience. In 1998, Ralf left Novartis to build and lead a team performing high-throughput discovery of therapeutic targets for neurological diseases at Biofrontera Pharmaceuticals, Leverkusen, a German biotech start-up. He became a Director of Technology development and took over responsibility to develop a high-throughput expression data analysis platform to automatically analyse large-scale qPCR data for quality aspects and disease relevant gene expression signatures. In 2003, he joined Philips Research in Germany, as a Principal Scientist responsible for the development of opportunities in the area of Molecular Diagnostics and Molecular Imaging. In 2004, he moved to Philips Research in Eindhoven to establish a project aiming at the identification of novel biomarkers for the diagnosis and prognosis of cancer diseases, in particular prostate cancer. As a PI of the prostate cancer biomarker activity at Philips, he was responsible for a number of external clinical and academic prostate cancer related collaborations on the European level. He was appointed honorary Senior Lecturer (Associated Professor) at Glasgow University in 2009 due to his substantial role in supervision of several Philips-BBSRC funded PhD students.
Head of Digital Technology & Innovation, Germany
Siemens Healthineers, Germany
Tobias Heimann is heading the German team of Siemens Healthineers global Digital Technology & Innovation department. Focus of the team is research of new algorithms and applications in the field of image analytics and AI. With 15 years of experience in the field in academia and industry, Tobias Heimann has worked on a large range of topics spanning statistical methods, machine learning, and computational modelling, and has co-authored more than 80 scientific publications.
Before joining Siemens, he received his PhD at the German Cancer Research Center in Heidelberg and worked as postdoctoral researcher at INRIA Sophia-Antipolis in France.
EMEA privacy consultant
Hans Martens is currently EMEA privacy consultant at Medtronic. Formerly, Regional Privacy Manager for Europa at GSK. Hans graduated from the Nijmegen University (Biochemistry) in The Netherlands. In 1994 he became employed by Eli Lilly and Company and held a variety of positions in Sales, R&D, IT, Auditing and Privacy till 2014. This included Privacy and Data Protection Manager in Europe and registered Dutch Data Protection Officer. In 2007 Hans has completed a Master on IT-auditing and obtained his CISA certification. Furthermore, Hans obtained CPGP, CIPT, CIPP/E and CIPM certification. Hans is a trained and certified fire fighter.
Vice President, Innovation Program Manager
Hans Hofstraat is Innovation Program Manager at Philips Research, a position he has held since 2009. As Innovation Program Manager, Hans works with teams within Philips Research, and with colleagues in Business and Markets, on innovations in the area of Oncology, Neurology, and Universal Access to Care, combining deep clinical insights with the opportunities offered by digital healthcare. Together with partners within and beyond Philips, Hans is passionate about identifying major needs in the health-technology domain, and to address these by developing meaningful solutions underpinned by proven outcomes. His aim is always to achieve innovations that broaden access to appropriate care and improve quality of life for patients and healthcare professionals.
Hofstraat holds several positions in (inter)national advisory bodies. Amongst others, he is a member of the Dutch Sounding Board for Horizon 2020, contributing to work on Health, Demographic Change and Well-being. He is a member of the Steering Committee and co-initiator of the big data initiative of Top Sector Life Sciences & Health. He is also a member of the Management Team of the Institute for Diagnostic and Interventional Imaging (IDII), in which Philips participates together with UMC Utrecht, University Utrecht, and TU Eindhoven. He is a member of the Supervisory Board of the European Institute of Innovation & Technology (EIT) Health, and a member of the European Scientific Panel for Health.
Hans joined Philips Research from Akzo Nobel Central Research in 1998. He has also worked as a (part-time) Professor at the Institute of Molecular Chemistry of the University of Amsterdam, and at the Public Works Department of the Dutch Ministry of Transport and Public Works in The Hague. He graduated with a PhD in physical chemistry from the Free University Amsterdam (thesis awarded with the Royal Dutch Shell prize), and was a post-doc at the Eidgenössische Technische Hochschule, Zürich, Switzerland. He worked as a lecturer at the Free University, the Free University Medical Center, and the University College of Swaziland in Kwaluseni while completing his studies. Hans has authored about 200 publications with an h-index of 42 (Google Scholar) and holds 10 granted US patents.
President and CEO
Peter Ohnemus is the founder of the dacadoo Health Score/dacadoo ag, Zurich/Switzerland. The patented dacadoo Health Score & Lifestyle Navigation Platform is being licensed to key Life & Health Insurance companies (Payers) and global healthcare operators (Providers). Peter has been involved in high-tech and bio-tech investments over the last 25 years and this had led to four IPO’s and multiple trade sells. Peter Ohnemus and his private investment firm Network Capital Holding are currently investing in high-tech and bio-tech start-ups. Peter was CEO & co-founded ASSET4 in 2004 with Goldman Sachs and Merrill Lynch as investors (the world’s leading provider of extra-financial information), which was sold to Thomson Reuters, New York in November 2009. Peter Ohnemus previously held senior executive positions with Sybase, Logic Works, The Fantastic Corporation and COS – all of which went public during his tenure. Peter Ohnemus was Entrepreneur of the Year (EoY) for Switzerland by EY. Peter is a frequent speaker and commenter on high-tech and healthcare globally. He has spoken at World Economic Forum (WEF), Fortune Brainstorm Health, Google Tech Talks, McKinsey’s Life Leaders CEO Forum, The Royal Society of Medicine, Stanford LIGHT Conference, CommunicAsia, Mobile World Congress, European Health Forum by the EU, Economist Global Healthcare Forum, Mobile Health Summit DC, European Tech Tour, Red Herring, WWW/Digital Disease Detection, etc. Over the last 10 years Peter has been board member of Rothschild Bank, Tele Denmark (Switzerland), Esbatech, CommerceOne, etc. Peter occasionally teaches digital innovation, entrepreneurship and economic impact at Universities such as HSG - Switzerland, Bocconi - India. Peter lives outside Zürich, is married and has 5 daughters.
Sr. Program Manager, Healthcare & Life Sciences
Google Cloud, USA
In 1982 I was diagnosed with a rare arrhythmia and that was the beginning of my journey as a heart patient. I was one of the first AV ablations at University California San Francisco hospital in 1983 and have been 100% pacemaker dependent for over 30 years.
As a lifelong heart patient, I did not want to become a victim of heart disease. Instead I wanted to pursue my goal to become an athlete and competitive cyclist. After having open chest surgery in 2010, doing any kind of physical activity was a frightening idea. However, with the help of wearable devices and mobile apps, I had the data I needed to get from the hospital bed to across the finish line of my first bike race. Since then I have competed in cycling events both domestically and internationally. My mission is to inspire others to do amazing things!
DNAnexus, Inc., USA
Richard has three decades of experience in building companies in healthcare and genomics, including 13 years at Baxter Laboratories. Subsequently to Baxter, Richard founded companies in both managed care and laboratory services and was also the CEO of Visible Genetics (NASDAQ: VGIN), the pioneer in laboratory-based gene sequencing and bioinformatics. Education includes a BS in finance from New York University and an MBA from Harvard University.
Distinguished Professor, University of Colorado
& Co-founder, Amgen, Applied Biosystems, USA
Marvin H. Caruthers is a Distinguished Professor at the University of Colorado. A Guggenheim Fellow, Dr. Caruthers completed the Ph.D. at Northwestern University and post-doctoral studies at MIT.
Professor Caruthers interests include nucleic acids chemistry and biochemistry. Approximately 35 years ago, the methodologies for chemically synthesizing DNA/RNA were developed in his laboratory and incorporated into instruments for synthesizing DNA/RNA as used by biochemists, biologists, and molecular biologists. More recently his laboratory has developed methods for RNA chemical synthesis and for the synthesis of DNA/RNA on chips. His laboratory has also pioneered the synthesis of many new nucleic acid analogs that have found applications in the nucleic acid diagnostic and therapeutic areas.
He is the recipient of several academic and research awards including The National Academy of Sciences Award in the Chemical Sciences, The Prelog Medal, The Economists Award in Biotechnology, and The US National Medal of Science. Dr. Caruthers is an elected member of The US National Academy of Sciences, The American Academy of Arts & Sciences, The National Inventors Hall of Fame, and a Corresponding Member of the German Academy of Science Gottingen. He is a co-founder of Amgen and Applied Biosystems.
Professor of Bioinformatics, Institute of Molecular Life Sciences (IMLS) and Swiss Institute of Bioinformatics (SIB), University of Zurich
Member of Global Alliance for Genomics and Health (GA4GH)
Michael Baudis is a Professor of Bioinformatics at the Institute of Molecular Life Sciences, University of Zurich, and a group leader at the Swiss Institute of Bioinformatics. Michael studied Medicine at Heidelberg University from which he graduated in 1998 and received his German medical license after internships at Heidelberg University Hospital. Between 1994 - 1998, he performed his research thesis in Molecular Cytogenetics in the group of Peter Lichter at the German Cancer Research Center (DKFZ) Heidelberg, on the genomic analysis of malignant lymphomas, in the context of a multi-center clinical trial. He received his doctorate of the Medical Faculty of the Ruprecht-Karls Universität Heidelberg in 1999. While working as an attending physician in Hematology & Oncology at Heidelberg University Hospital between 1998 and the end of 2000, Dr. Baudis pursued research projects in molecular cytogenetics and biology of hematologic neoplasias, and started to collect genomic profiling data from Comparative Genomic Hybridization (CGH) experiments. In January 2000, he began a postdoctoral research project at Stanford University, in the group of Prof. Michael Cleary (Department of Pathology) with focus on the functional characterisation of E2A-HLF and E2A-PBX1 fusion genes in acute lymphoblastic leukemias, using in vitro cell line models with inducible constructs and array based gene expression analysis as well as murine essays. This work was extended during the following faculty position at the University of Florida. Already during his thesis at the DKFZ, Michael became interested in the systematic collection of genome screening data, then from the CGH experiments performed at the Lichter lab. Supported by an internal grant from the University of Heidelberg's Medical School, he was able to create a database of original and publication derived genomic copy number data from malignant lymphomas. The website of the progenetix.net molecular cancer cytogenetics website was launched in early 2001, accompanied by a publication in Bioinformatics. Following a brief stay at the RWTH Aachen (Human Genetics; 2006-2007), since August 2007 Michael has been a group leader and Professor of Bionformatics (2015) at the Institute of Molecular Life Sciences of the University of Zürich, as well as associated with the Swiss Institute of Bioinformatics SIB. The work of his _Computational Oncogenomics_ group is centered on the comparative analysis of genomic profiling data in cancer, with a focus on somatic copy number variations (CNV, CNA). With the Progenetix and arrayMap repositories, the group provides some of the largest reference resources of curated genomic profiling and associated metadata covering the majority of cancer types. Apart from the analysis of cancer genome data, in recent years Michael has been involved in efforts to facilitate the access to genomic data for research on a global scale. Since its founding in 2014, Michael has been a member of the Global Alliance for Genomics and Health GA4GH, currently serving in the steering committee and as co-lead of its "Discovery" workstream. Related to the work in the Global Alliance, Michael also co-chairs the ELIXIR Beacon project, which develops APIs to query genomic data collections in a privacy-protecting manner. Here, the main focus on the group is in prototyping protocol extensions with demonstrator implementation in the Beacon+ project, connected to the Progenetix and arrayMap repositories. In the Swiss context, Michael has been involved in advising the Swiss Personalized Health Network (SPHN) initiative and currently leads its "Bioinformatics and Data Analytics" working group.
Clinical Informatics Research Unit, University of Southampton
Tim Gibbons has worked as a Research Fellow in the Clinical Informatics Research Unit at the University of Southampton since 2011. He has expertise in application design, NHS information governance and research system integrations. Tim Gibbons will discuss a 20 year programme of work from the University of Southampton in the management and development of local and national research systems. Tim will present the programme’s evolution through technological, political and research landscape changes into its current multi-national collaborative application.
Centre Head, Quantitative Biology Center Tübingen, Germany
Dr. Nahnsen studied Biomathematics and Biotechnolgy at the Universities Greifswald (Germany), Strasbourg (France) and Cambridge (UK). He received his PhD in Computer Science from the University of Tübingen in 2010. For many years he has been working at the interface of computer science and the biomedical sciences. He developed software solutions, as well as mathematical approaches for the analysis of modern high-throughput data. In 2012, he accepted the position as the head of the newly established Quantitative Biology Center (QBiC) in Tübingen. Together with his team he developed automated solutions for data and project management for clinical studies as well as bioinformatics methods for the integration of multi-scale omics data.
Professor in Bioinformatics, Director of the Biotechnological center
Technical University Dresden, Germany
Michael Schroeder is a professor in bioinformatics and director of the biotechnological center of the Technical University Dresden. He has published some 200 papers and led numerous international research projects. He obtained his PhD in Computing from University of Hanover. From 2005 to 2015 he was CSO of Transinsight GmbH.
Chair, European Connected Health Alliance, UK
Brian O’Connor was born in Belfast, Northern Ireland and has developed his career as a consultant, manager and/or investor in both private and public companies.
Brian has worked in the UK, the US and lived in Hong Kong for eleven years. He has gained vast experience as a company director in a variety of industries and professions, and has raised significant sums for companies through both private equity structures and stock exchange listings.
Through his long established consultancy company, Corporate Direction Ltd, he is currently providing strategic advice to Governments, International organisations and companies on the challenges facing healthcare in general and specifically on the Connected Health opportunity.
Brian has founded a number of companies in the healthcare services area in the UK, Ireland and Hong Kong. He therefore has experience of the public and private health care systems in a number of countries and also an understanding of the often difficult balance between delivering care and making profit. He believes that overcoming the cultural and other barriers within healthcare is an interesting if sometimes frustrating challenge, but worthwhile if it leads to better patient care.
Brian is Chair of the European Connected Health Alliance organisation www.echalliance.com the rapidly expanding not for profit membership organisation.
It has created an International Network of Permanent Connected Health Ecosystems throughout Europe, to provide sustainable and structured opportunities for industry, academia and health and care providers and payers to meet and provide solutions to specific problems.
Founder & CEO, Patient In Focus
Charlotta Nørgaard started her healthcare career as a manager at the biotech giant, Genentech, in San Francisco, California in 2003. She directed the renowned Access Solutions department and led 6 drug launches. Later, she became the head of several consultancies incl. WG Consulting, a division of Gray Healthcare (a WPP company) with a focus on patient access, coverage and reimbursement, market access and HEOR.
Personal struggle with chronic diseases (including Systemic Lupus Erythematosus, arthritis, eczema and Hashimoto) led to Charlotta creating Lupus Friends and Family Foundation, a global non-profit patient organization that helps thousands of patients.
Charlotta is a public speaker, a clinical trial participant, a Wego Health Awards nominee (2016-2018) and a true co-creator in drug development. Her knowledge is sought after and her reach to other patients exceptional.
As a Patient Expert, Charlotta is recruited by public and private organizations in the US and Europe incl. hospitals, research centers, pharma, patient organizations, CROs, and even the National Institutes of Health (NIH) to ensure the patient voice is heard.
She has been actively involved in all areas of advocacy and activism to secure government funding for research, change state law to benefit the chronic ill, and to make a difference in patients’ lives. It is this passion that led her to found Patient Protocol, a mHealth company, that was instrumental in her own disease pathway. The company became successful in revolutionizing the clinical trial process by using a patient reported outcomes (PRO) program during washouts to achieve excellent trial results.
Charlotta has been featured in several publications incl. Journal of American Medical Association (JAMA) and is soon to be published for her research involvement as well.
She is the Chair of EUPATI Denmark, a EU Commission supported patient organization focusing on bringing clinical research and development education to patients to increase patient engagements. And she will be a EUPATI Fellow as of September 2018.
Managing Director, Center for Research and Interdisciplinarity (CRI), France
Board member Healthcare Data Institute
Isabelle Hilali is CRI - Center for Research & Interdisciplinarity’s Managing Director. CRI is a unique place that experiments and spreads new ways of learning, teaching, conducting research and mobilizing collective intelligence in life, learning and digital sciences. She is also Board Member of the Healthcare Data Institute, a think tank, that gathers
a large community of big data and health experts. As a true and positive leader, she is a dedicated professional committed to the health and education fields. Before joining CRI, Isabelle held several senior management positions in the eHealth field as well as in the mobile and internet industry, both in France and internationally. She holds a Masters
degree from “Institut d’Etudes Politiques (Sciences Po) de Grenoble” and “Université Paris I - Panthéon Sorbonne” in Military Strategy.
Director of Innovation and Development
NHS Foundation Trust, UK
Professor Helen Rostill is a Consultant Clinical Psychologist and Board Director at Surrey and Borders Partnership NHS Foundation Trust with responsibility for strategy, new business, research and development, innovation, information technology strategy and therapies. She is the Trust’s Chief Technology Officer. Helen currently leads mental health programmes in Surrey Heartlands and Frimley integrated care systems. She is the Senior Responsible Officer for the TIHM (Technology Integrated Health Management) for dementia national Test Bed sponsored by NHS England and the Department of Health. She worked for 10 years as a Senior Lecturer at the University of Birmingham and has published a wide range of research in national and international peer reviewed journals. Her qualifications include a Doctorate in Clinical Psychology (Clin PsyD), a Postgraduate Diploma in Strategic Management and Leadership, and a BSc (First Class Hons) in Psychology. Helen is visiting Professor at the faculty of Health and Medical Sciences at the University of Surrey.
Chief Technology & Innovation Officer
Inselspital, University Hospital Bern, Switzerland
Fried-Michael Dahlweid is the director of technology and innovation of the Insel-Group, the largest Swiss healthcare delivery organization, including the university hospital of Bern. He is a board-certified emergency and trauma care physician, and graduated in both, medical informatics as well as in strategy, design thinking, and business administration. Before joining the university hospital Bern, he served as global chief medical officer for GE Healthcare and DXC Healthcare, respectively. Previously he ran different health IT software businesses operationally, including health software production at AGFA Healthcare, and served at the helm of large hospital groups’ IT businesses. He started and operated health tech start-ups and holds different board seats in the venture and health tech industry. Additionally, he has taken on advisory roles for international Governments, and acts as a lecturer at various universities.
Chief Digital Officer and Senior Vice President for Technology Innovation and Consumer Experience
Thomas Jefferson University and Jefferson Health System
Neil Gomes (B.Sc., MBA/MMS, M.Ed) is the Senior Vice President for Technology Innovation and Consumer Experience and Chief Digital Officer at Thomas Jefferson University and Jefferson Health System. Neil has worked for the Fortune 500 Tata Group of Companies where he played a leadership role in building the intrapreneurial startup, Tata Interactive Systems, from 60 employees to the world’s largest custom e-learning development firm with 650 employees in less than two years. Neil left the Tata Group to complete his M.Ed. in Instructional Design at the University of South Florida (USF) whilst progressively working towards the position of Director of eTeaching and Technology and then the Director of Instructional Design and Training at USF Health. While at USF, Neil’s leadership and entrepreneurial acumen helped grow a strategic team of application developers, instructional and multimedia designers, and project managers that generated over $1.5 million in annual auxiliary revenue from research and external development projects while growing online student enrollment from approx. 200 enrollments in 2002 to 60,000 enrollments a semester by 2012. While at USF, Neil also began working toward his Ph.D., is currently a Ph.D. Candidate (ABD), has authored research articles, a book chapter, and delivered several formal research presentations. At Jefferson, Neil drives digital innovation in healthcare, consumer experience and engagement, training, and education via teams of application and web/mobile developers, portal solutions developers, simulation and UI/UX designers, trainers, documentation and digital consumer experience specialists,instructional designers, e-learning developers, and IT support specialists. Neil also helps define innovation strategy and design innovation development programs via Jefferson’s Innovation Team. Recently, he helped secure a $15 million donor grant from the Bernie Marcus Foundation to develop a high-tech, consumer-centric, integrative health center at Jefferson and also launched a pioneering collaboration with the IBM Watson IoT team on developing “cognitive concierges” for hospitals.
Neil serves as Associate Editor of the Journal for Healthcare Transformation and is a contributor toward the book: We CAN fix Healthcare, the Future is NOW. Neil is also a speaker, agile aficionado, and digital innovation evangelist.
Professor of Machine Intelligence
University of Surrey, UK
Payam Barnaghi is Professor of Machine Intelligence at the University of Surrey. He is also technical lead for the TIHM for Dementia project, sponsored by NHS England and the Department of Health, and was coordinator and Principal Investigator of the EU FP7 CityPulse project on smart cities and large-scale data analytics. He is an associate editor of the IEEE Transactions on Big Data. He works on machine learning, Internet of Things (IoT), semantic web, service computing, adaptive algorithms, big data and information search and retrieval to solve problems and develop new technologies for the future Internet/Web and healthcare systems.
Senior Application Scientist
Akos Tarcsay has nearly 10-year experience in computational chemistry and cheminformatics. He spent 6 years as drug designer at Gedeon Richter Plc. and 4 years in cheminformatics field as Senior Application Scientist at ChemAoxn. His current responsibility is suggesting solutions to research informatics challenges relying on the ChemAxon portfolio. Msc in chemical engineering and biochemical engineering, PhD on the field of computational chemistry from Budapest University of Technology and Economics. Author or co-author of >15 publications.
Deloitte UK Centre for Health Solutions
Mark is a Research Manager in the Deloitte UK Centre for Health Solutions. He supports Deloitte’s Life Sciences and Health Care practices in identifying emerging trends, challenges, opportunities and examples of good practice, based on primary and secondary research and rigorous analysis. Until November 2016, he was the Institute Manager and a Policy Fellow at the Institute of Global Health Innovation at Imperial College London, where he supported research on palliative and end-of-life care, maternal and child health, design, philanthropy and electronic health records. Mark has a PhD from the UC Berkeley - UCSF Graduate Programme in Bioengineering, and he completed a Whitaker International Postdoctoral Fellowship in the Departments of Materials and Bioengineering at Imperial College London.
(Only available for corporate registrations)
For more information click here to learn more: https://www.nextlevells.com/membership